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To guide development of new drugs targeting me-
thionyl-tRNA synthetase (MetRS) for treatment of
human African trypanosomiasis, crystal structure
determinations of Trypanosoma brucei MetRS in
complex with its substrate methionine and its inter-
mediate product methionyl-adenylate were followed
by those of the enzyme in complex with high-affinity
aminoquinolone inhibitors via soaking experiments.
Drastic changes in conformation of one of the two
enzymes in the asymmetric unit allowed these inhib-
itors to occupy an enlarged methionine pocket and a
new so-called auxiliary pocket. Interestingly, a small
low-affinity compound caused the same conforma-
tional changes, removed the methionine without
occupying the methionine pocket, and occupied
the previously not existing auxiliary pocket. Analysis
of these structures indicates that the binding of the
inhibitors is the result of conformational selection,
not induced fit.
INTRODUCTION
Human African trypanosomiasis (HAT) affects 50,000–70,000
inhabitants of Sub-Saharan Africa (Brun et al., 2010), with
60 million people at risk of infection (Hotez et al., 2007). HAT is
caused by the protozoan Trypanosoma brucei. Left untreated,
the disease is uniformly fatal. Current therapeutic options have
many shortcomings (Brun et al., 2010). Consequently, we aim
to develop effective, safe, easy to administer, and affordable
drugs for treating the disease by targeting aminoacyl-tRNA
synthetases (aaRS). AaRSs are crucial for protein synthesis in
all organisms (Ibba and Soll, 2000). Blocking aaRS function
inhibits the proper charging of tRNAs leading to disruption of
translation. The essential role of aaRSs thus presents opportuni-
ties for the development of new antimicrobials (Critchley et al.,
2009; Critchley and Ochsner, 2008; Ochsner et al., 2007;Structure 20, 1681–1Pohlmann and Bro¨tz-Oesterhelt, 2004; Vondenhoff and Van
Aerschot, 2011).
Methionyl-tRNA synthetase of T. brucei (TbMetRS) is one of
our top targets for antitrypanosomal drug design because of
substantial sequence differences with the mammalian orthologs
in the active site. We have validated MetRS as a drug target
by RNAi (Shibata et al., 2011) and obtained a series of inhibitors
with an aminoquinolone scaffold similar to two bacterial MetRS
inhibitors (Critchley et al., 2009; Critchley and Ochsner, 2008).
These inhibitors selectively inhibit TbMetRS and the growth of
bloodstream form T. brucei in culture with EC50 values as
low as 4 nM but with minimal effects on mammalian cells.
One inhibitor was shown to have antitrypanosomal activity in
a mouse model (Shibata et al., 2011). To provide a structural
platform to assist further anti-TbMetRS drug development,
eight structures of TbMetRS in complex with its substrate
methionine (Met), with the intermediate product methionyl-
adenylate (MAMP), with five inhibitors, and with a ‘‘fragment’’
of the inhibitors were determined (Table 1). Diffusing inhibitors
and fragment into substrate-bound TbMetRS crystals caused
large conformational changes in one but not the other subunit
in the asymmetric unit.
The mechanism of conformational changes in proteins upon
binding to large and small molecules is currently a hotly debated
issue. For more than 50 years, the ‘‘induced-fit’’ model (Kosh-
land, 1958), where the ligand binds and thereby induces changes
in conformation has been widely accepted (Boehr and Wright,
2008; Csermely et al., 2010). Several more recent reports
support, however, ‘‘conformational selection,’’ also called con-
formational sampling, population shift or fluctuation fit (Bakan
and Bahar, 2009; Boehr et al., 2009; Changeux and Edelstein,
2011; Csermely et al., 2010; Gsponer et al., 2008; Koglin et al.,
2008; Lange et al., 2008; Tang et al., 2007), as an alternative
mechanism. In this paradigm, a protein is thought to be present
in an ensemble of multiple conformations in the absence of
ligand, and the ligand binds to one of these preexisting ligand-
free conformations. The eight structures reported here, when
combined with previously known ligand-free structures of
related enzymes, provide a platform to compare the two mech-
anisms of ligand binding.691, October 10, 2012 ª2012 Elsevier Ltd All rights reserved 1681
Table 1. Data Collection and Refinement Statistics
TbMetRS,Met TbMetRS,MAMP TbMetRS,1289 TbMetRS,1312 TbMetRS,1320 TbMetRS,1325 TbMetRS,1331 TbMetRS,89
Data collection
Space group P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121
Cell dimensions
a, b, c (A˚) 85.0, 105.9, 207.2 85.5, 105.9, 208.4 87.5, 105.9, 207.6 86.9, 106.1, 207.4 86.5, 105.9, 207.6 86.6, 105.6, 207.4 89.2, 105.7, 205.9 87.9, 105.7, 206.6
Resolution (A˚) 50–2.90 50–2.95 50–3.10 50–3.10 50–2.70 50–2.90 50–2.75 50–2.60
(3.0–2.90)a (3.06–2.95) (3.15–3.10) (3.21–3.10) (2.75–2.70) (3.0–2.90) (2.80–2.75) (2.64–2.60)
Rmerge 0.14 (0.73) 0.21 (0.99) 0.19 (0.72) 0.24 (0.87) 0.14 (0.82) 0.17 (0.67) 0.14 (0.76) 0.15 (0.76)
Rpim 0.06 (0.30) 0.09 (0.39) 0.10 (0.34) 0.11 (0.37) 0.06 (0.33) 0.09 (0.34) 0.07 (0.36) 0.08 (0.34)
CC*b 1.0 (0.96) 1.0 (0.94) 1.0 (0.93) 0.99 (0.90) 1.0 (0.93) 1.0 (0.94) 1.0 (0.91) 1.0 (0.92)
I / sI 12.4 (2.0) 8.9 (1.9) 9.1 (1.9) 6.7 (1.6) 11.6 (1.9) 8.6 (2.1) 10.1 (2.1) 10.5 (2.0)
Completeness (%) 99.9 (100) 99.9 (100) 99.7 (100) 99.5 (98.9) 99.6 (99.2) 99.9 (100) 97.8 (97) 99.9 (99.6)
Redundancy 6.1 (5.7) 6.4 (6.4) 4.5 (4.3) 6.1 (5.7) 6.2 (6.1) 4.3 (4.3) 3.9 (3.8) 5.0 (5.0)
Refinement
Resolution (A˚) 30–2.90 30–2.94 30–3.15 30–3.10 30–2.70 30–2.90 30–2.75 30–2.60
No. reflections 39,977 38,631 32,066 33,506 49,997 40,543 47,066 56,834
Rwork / Rfree 0.209/0.254 0.212/0.266 0.191/0.240 0.202/0.258 0.188/0.228 0.190/0.243 0.182/0.230 0.177/0.224
No. atoms
Protein 8,495 8,435 8,257 8,221 8,480 8,368 8,561 8,542
Met or MAMP 18 62 9 9 9 9 9 9
Inhibitor – – 28 25 27 34 23 12
Solvent ligand/ion 72 66 149 137 135 115 130 140
Water 81 103 169 180 302 217 310 461
B-factors
Protein 48.5 58.7 44.9 38.0 54.5 43.0 40.4 43.6
Met or MAMP 28.3 46.2 27.7 11.9 39.1 28.6 26.8 32.3
Inhibitor – – 44.6 32.2 49.9 43.5 30.2 31.2
Solvent ligand/ion 57.0 63.4 56.1 40.9 71.6 60.3 60.6 67.1
Water 31.4 34.0 27.1 20.4 47.0 26.3 29.8 38.0
Rmsds
Bond lengths (A˚) 0.008 0.007 0.008 0.008 0.008 0.007 0.008 0.008
Bond angles () 1.16 1.12 1.19 1.21 1.19 1.13 1.18 1.18
aValues in parentheses are for highest-resolution shell.
bCC* should be close to 1.0 but, as demonstrated by Karplus and Diederichs (2012), even CC* values as low as 0.4 indicate significant useful signal.
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Figure 1. The Structure of TbMetRSdMet
TbMetRS,Met has two subunits in one AU (sepa-
rated by the dashed line). Each subunit has four
domains typical of MetRS: the Rossmann fold
(green), CP domain (cyan), SCF (red), and the
anticodon binding helix bundle (pink). The first part
of the CP domain is further divided into the CP
base (olive) and CP knuckle (deep blue). Met
bound in the active site is shown in CPK model.
See also Figures S1, S2, S3, S4, and S5 and
Table S1.
Structure
Inhibitor Binding by T. brucei Met tRNA SynthetaseRESULTS
The Synthetase in Complex with Met and MetAMP
The TbMetRS,Met crystals contain two copies of the enzyme
in the asymmetric unit (AU) (Figure 1). TbMetRS is characterized
by several key structural features: (1) a Rossmann fold catalytic
core with an inserted connective peptide (CP) domain; (2)
a stem-contact fold (SCF) domain containing the conserved
KMSKS signature (KISKS in trypanosomatids); and (3) an
anticodon binding a helix bundle. Of special interest is the
CP domain that in TbMetRS harbors one ‘‘knuckle,’’ which
defines TbMetRS as member of the MetRS1 subfamily (Gentry
et al., 2003; Green et al., 2009). (MetRSwith two knuckles belong
to the MetRS2 subfamily.) The structure of TbMetRS,Met is
closest to that of Leishmania major MetRS in complex with two
intermediate products (LmMetRS,MAMP,PPi,Mg
2+) (Larson
et al., 2011). However, in the TbMetRS,Met structure, the
enzyme adopts a slightly more open active site conformation
than in the LmMetRS,MAMP,PPi,Mg
2+ complex (Figure S1
available online).
There is no major difference between the structures of the two
subunits in the AU of TbMetRS (rmsd of 0.40 A˚) except for a slight
displacement in part of the CP domain (Asp353 to Arg408) in
subunit B. For the purpose of the discussion below, we further
divide this first part of CP domain into two segments: the antipar-
allel b-stranded ‘‘base,’’ spanning Asp353 to Tyr363 and Thr398
to Arg408, and the knuckle, formed by residues Ser364 to
Val397. Four residues at the tip of the knuckle in subunit B are
disordered, while these residues are well defined in subunit A
(Figure S2).
Well-defined, and very similar, electron densities for Met are
found in the active sites of both subunits in the AU (Figure S3).
The Met binding pockets of TbMetRS in the two subunits
are essentially the same and the protein adopts a conformation
as observed in other MetRS structures in complex with Met
(Ingvarsson and Unge, 2010; Serre et al., 2001) (Figure S4 and
Table S1).
Upon soaking of Met, ATP, and Mg2+ into the TbMetRS,Met
crystals, the intermediate product MAMP is formed in the
crystal and occupies the active site in each of the two sub-
units in the AU in the same manner (Figure S5). The overall
structure of the TbMetRS,MAMP complex remains close to
that of TbMetRS,Met, with an rmsd of 0.28 A˚ for the twoStructure 20, 1681–1691, October 10, 2012 ªsubunits (Figure S1). The structure of
TbMetRS,MAMP demonstrates access
of ligands to both active sites in thecrystal lattice, opening an avenue to study inhibitor binding
through soaking experiments.
The Synthetase in Complex with Inhibitors
Five potent inhibitors of TbMetRS, with low nanomolar EC50
values in T. brucei cell culture (Shibata et al., 2011), were soaked
into TbMetRS,Met crystals. In an aminoacylation assay, the IC50
values of these inhibitors range from 8 to 65 nM, and correlate
well with both the EC50 and the ability to change the melting
temperature of the protein (DTm) (Table 2). All inhibitors contain
a substituted benzyl group connected by a linker to an aminoqui-
nolone (1289, 1312, and 1320) or to a benzimidazole (1331 and
1325) moiety.
The results of the inhibitor soaks were a complete surprise,
since the two MetRS subunits per AU behaved very differently
toward the molecules introduced. While Met was retained in
subunit A in all cases, each of the inhibitors replaced Met in
subunit B and adopted a common binding mode (Figure S6).
Typically the benzyl/phenyl group occupies now a larger Met
pocket called hereafter the ‘‘enlarged Met pocket’’ (EMP)
(Figures 2A and 2B). Extending through the linker, the aminoqui-
nolone or benzimidazole moiety of the inhibitors is inserted into
a nearby pocket that was previously neither present in the
TbMetRS,Met nor in the TbMetRS,MAMP structure. For ease
of discussion, we call this the ‘‘auxiliary pocket’’ (AP) (Figures
2C and 2D). Accompanying the enlargement of the Met pocket
and the formation of the AP are extensive positional changes,
some of these changes involve residues located more than
30 A˚ away from the active site center, with over 80 residues shift-
ing by up to 13 A˚. These changes are manifold and include: (1)
side-chain rearrangements of residues in the Met pocket and
the AP; (2) displacements of at least 35 residues in helices
a-2, a-3, a-7 and between strands b-10 and b-11 in the Ross-
mann fold to form the AP; and (3) a large movement of the
CP domain, which creates access to the AP (Figure 2E; Tables
S2, S3, and S4).
The substituted benzyl group and the linker part of the inhibi-
tors occupy the hydrophobic EMP. Several hydrophobic side
chains (Tyr250, Val473, Trp474, and Phe522) that delineated
the smaller Met pocket have moved outward by 2.4–6.7 A˚ to
form the larger EMP (Figures 2A, 2B, and 3A; Table S2). Two
sub-pockets within the EMP can be discerned. The first was
originally filled by the sulfur atom of Met in the TbMetRS,Met2012 Elsevier Ltd All rights reserved 1683
Table 2. Compound ID, Structures, and Activity
*Concentration used for DTm determination is 50 mM in the presence of 10 mM Met, ATP, and Mg
2+ instead of 100 mM used for the other inhibitors.
**Concentration used for DTm determination is 800 mM against TbMetRS in the absence of Met, ATP, and Mg
2+.
Structure
Inhibitor Binding by T. brucei Met tRNA Synthetasestructure. A bromine (1289 and 1320), chlorine (1312 and 1331),
or oxygen (1325) atom occupies, in the TbMetRS,inhibitor
structures, essentially the same position as the sulfur atom in
the TbMetRS,Met structure (Figures 3B and S7A). Another
substitution on the ring, typically a halogen atom, fills the
second, new, hydrophobic subpocket in the EMP created by
the shifts of Val473, Trp474, and Phe522. The side-chain
hydroxyl oxygen of Tyr250 moves by not less than 6.5 A˚, result-
ing in a stacking of its phenol ring against the aminopropyl linker
of the inhibitors (Figures 3B and 3C). Otherwise no specific inter-1684 Structure 20, 1681–1691, October 10, 2012 ª2012 Elsevier Ltdactions can be observed for the largely solvent exposed linker,
explaining the relatively weak density for this part of themolecule
(Figure S6).
The AP is nonexistent in the TbMetRS,Met structure (Fig-
ure 2C) and therefore the aminoquinolone or benzimidazole
moiety of the inhibitors would clash in many ways with multiple
residues in the substrate-bound conformation of TbMetRS (Fig-
ure 3A). Two of the many conformational changes occurring are
mainly responsible for creating the AP. First, a rotation of 30
by the CP hinges on residues Tyr355 and Tyr405 near bothAll rights reserved
Figure 2. Structural Changes in TbMetRS
upon Binding of Inhibitors
(A) Protein surface of TbMetRS,Met subunit B
(pale cyan). Surface that will form the EMP upon
binding of inhibitors is colored blue.
(B) Identical view as (A) showing the protein
surface of TbMetRS,1320 subunit B (white). Note
the enlargement of the narrow Met pocket seen in
(A), to the EMP (blue) as well as formation of the
AP, which is nonexistent in (A).
(C) A 30 rotation view of (A) about the indicated
axis, to better show the absence of the AP (red).
Residues that would be within a 4.5 A˚ radius of
1320 upon binding of the inhibitor are shown in
stick. The boundary of the CP knuckle is indicated
by a dashed line.
(D) A 30 rotation view of (B) about the indicated
axis, to better show the formation of the AP (red).
Note the rearrangement of many residues in
the formation of the AP, including the displace-
ment of the CP knuckle (dashed line) away from
the active site.
(E) The extensive conformational changes in
TbMetRS upon binding of inhibitor. TbMetRS,Met
subunit B (green) is superimposed with
TbMetRS,1320 subunit B (sand); parts of the
backbone that undergo significant displacement
are traced as red on TbMetRS,1320. Movements
are highlighted with arrows.
See also Tables S2, S3, and S4.
Structure
Inhibitor Binding by T. brucei Met tRNA Synthetaseends of the antiparallel b strand CP base, thereby moving
away from the active site and providing access to the AP (Fig-
ure 2E). Second, multiple helices in the Rossmann fold shift to
form the AP (Table S3). The aminopropyl linker adopts an
extended conformation and the planar aminoquinolone/benz-
imidazole moiety of the inhibitors is inserted between the
N-termini of helices a-2 and a-7 in the Rossmann fold (Figure 2E).
The movements of Tyr250, Gly290, Glu368, and Val473 are
particularly crucial since their original position in the substrate-
bound structures would severely clash with the aminoquinolone
or benzimidazole moiety (Figures 2C and 2D). The displacement
of Glu368 in the CP domain exposes the AP. Finally, the flip of the
Tyr250 side chain creates a groove that connects the EMP and
AP. The large displacement of the CP domain needed for access
to and formation of the AP probably explains why inhibitors areStructure 20, 1681–1691, October 10, 2012 ªonly observed in subunit B in the AU,
since such a repositioning of the CP
domain of subunit A is precluded by
packing contacts in the crystals
(Figure S2).
Eleven residues, mainly hydrophobic,
define the AP (Table S4). The insertion of
an aminoquinolone/benzimidazole ring
into the AP is stabilized by multiple
stacking interactions (Figure 3C). The
aminoquinolone/benzimidazole ring is
sandwiched between the side chains of
Tyr250 and Val473, as well as the
Tyr472-Val473 and His289-Gly290 pep-
tide units. In addition, the indole ring ofTrp474 stacks on top of Val473. These largely planar features
of the enzyme form the walls of the pocket. The depth of the
pocket is mainly determined by His289, Leu456, Ala460,
Tyr472, and Asp476. The phenol ring of Tyr472 swings toward
the inhibitors forming the new boundary for the AP. Side chains
of Tyr250, Val473, and Trp474 all shift by at least 3.2 A˚ compared
to the substrate-bound conformation. Importantly, Asp287
moves toward to the inhibitor, forming critical hydrogen bonds
with the two NH donors from the AP occupying moieties of all
inhibitors (Figure 3D and Figure S7B).
The Synthetase in Complex with a ‘‘Fragment’’
A low molecular weight compound, 2-amino-8-hydroxy-quino-
line (89) was also used successfully in a soaking experiment.
Compound 89 is a poor inhibitor, as it was found to increase2012 Elsevier Ltd All rights reserved 1685
Figure 3. Stereoviews of Interactions
between TbMetRS and Inhibitors
(A) Side-chain rearrangements in TbMetRS active
site. TbMetRS,Met subunit B (green) is super-
imposed with TbMetRS,1320 subunit B (sand).
Met (magenta) and 1320 (light pink) are shown in
ball and stick. Residues within a 4.5 A˚ radius of
1320 are shown in stick. Significant rearrange-
ments are indicated with arrows, and side chains
moving are labeled.
(B–D) Superpositions of all TbMetRS,inhibitor
structures show a common binding mode. All in-
hibitors are depicted in ball and stick; residues
within a 4.5 A˚ radius of inhibitors are shown in stick.
TheTbMetRS,inhibitorpairs arecoloredas follows:
TbMetRS,1289 – cyan, orange; TbMetRS,1312 –
deepblue,paleyellow;TbMetRS,1320–sand, light
pink; TbMetRS,1331 – deep purple, wheat;
TbMetRS,1325 – lemon, light blue; Met (magenta)
is shown as reference. (B) The substituted benzyl
provides a hydrophobic moiety that is inserted into
the hydrophobic EMP. The Br, Cl, or O atom
occupies a position very close to that of the sulfur
atom of the substrate Met (shaded). (C) The planar
ring systems in the aminoquinolone or benzimid-
azole inhibitors play an important role in stacking
interactions, filling the deep auxiliary pocket (AP)
(shaded). (D) The two critical hydrogen bonds
between Asp287 carboxylate and the nitrogens
on the aminoquinolone and benzimidazole ring
systems (2.6–3.3 A˚) of the inhibitors.
See also Figures S6 and S7.
Structure
Inhibitor Binding by T. brucei Met tRNA Synthetasethe melting point of TbMetRS by only 1.8C at 0.8 mM, which is
a much smaller change in melting temperature than observed
for the other inhibitors, despite being used at higher concentra-
tion (Table 2). Compound 89 binds exclusively to the AP of
subunit B (Figure 4A). Quite unexpectedly, even though none
of the atoms of 89 are placed in the EMP, the Met pocket
has become larger and the Met bound initially has disappeared
(Figure 4B). A glycerol molecule from the cryosolution fills part1686 Structure 20, 1681–1691, October 10, 2012 ª2012 Elsevier Ltd All rights reservedof the EMP (Figure S8). In sharp contrast,
in subunit A, Met is retained, the Met
pocket is unchanged in size, and no
compound 89 is bound. In spite of the
much lower affinity of compound 89 for
TbMetRS than the other inhibitors, the
structure of TbMetRS subunit B binding
89 is very similar to the structures of
subunit B bound to the larger inhibitors.
The molecule, an aminoquinoline, binds
to the AP in the same way as seen
before by the aminoquinolone moiety of
the inhibitors although it lacks, com-
pared to the inhibitors, the linker and
the substituted benzyl moiety that tar-
gets the EMP (Figure 4). All the move-
ments of side chains, main chain, and
secondary structure elements involved
in the formation of EMP and AP upon
binding compound 89 are remarkablysimilar to movements observed upon binding of the inhibitors
(Figure 4E; Tables S2, S3, and S4).
DISCUSSION
The structures reported here reveal a considerable structural
plasticity of the TbMetRS enzyme even in the crystalline state.
The enzyme can adopt dramatically different conformations
Figure 4. The Binding of Compound 89 to
TbMetRS
(A) Surface representation of TbMetRS,89 subunit
B (yellow) reveals that compound 89 (forest) binds
exclusively to the AP (red).
(B) An alternative view of the pockets in
TbMetRS,89 subunit B (yellow) show that Met has
been displaced and the methionine pocket is
enlarged to form the EMP, although none of the
atoms of compound 89 are present in the EMP.
(C) Identical view and surface coloring as panel (A):
TbMetRS,89 subunit B with inhibitor 1320 from
TbMetRS,1320, after superposition of subunits B
from both complexes. Compound 89 as ball and
stick; 1320 in light pink stick.
(D) Identical view and surface coloring as panel b:
TbMetRS,89 subunit B with inhibitor 1320 from
TbMetRS,1320, after superposition of subunits B
from both complexes. Compound 89 as ball and
stick; 1320 in light pink stick.
(E) Superposition of TbMetRS,89 subunit B
(yellow) with TbMetRS,1320 subunit B (sand) in
stereo. Compound 89 (forest) and inhibitor 1320
(light pink) are shown as ball and stick. Confor-
mations of residues within 4.5 A˚ of 1320 are
identical in both structures except for a slight
displacement of E368 as it is located in the flexible
CP domain.
See also Figure S8.
Structure
Inhibitor Binding by T. brucei Met tRNA Synthetasedepending on the type of ligand bound. The eight crystal struc-
tures presented here correspond globally with three states:
(1) The Met-bound M-state characterized by a small Met
pocket, a closed CP domain, an open/flexible KISKS
motif, and a nonexisting AP;
(2) The MAMP-product bound P-state, with a small Met
pocket, closed CP domain and a closed KISKS motif,
while the AP is nonexistent.
(3) The inhibitor-bound I-state, where the Met pocket is
enlarged, forming the EMP, the CP domain is open, the
KISKS motif is flexible, and the AP is formed. Drastic
changes of the I-state compared to the M-state involve
backbone shifts of domain and secondary structure
elements, combined with small and large side-chain
movements (Figures 2 and 3; Tables S2, S3, and S4).
The ability of inhibitors to trigger somany changes despite
the enzyme being in the crystalline state is highly unusual.
In our case, the set of structures elucidated provides in
addition a unique opportunity to arrive at a mechanism
for the conformational changes observed.
Two global mechanisms have been proposed when binding of
a ligand to a protein results in conformational changes of theStructure 20, 1681–1691, October 10, 2012 ªprotein upon forming a protein,ligand
complex: induced fit and conformational
selection (Boehr et al., 2009; Boehr and
Wright, 2008; Changeux and Edelstein,
2011; Csermely et al., 2010). An
induced-fit mechanism explaining the
conformational changes going from the
M-state in the crystals to the I-state(Figures 5A and 5B) would require that the MetRS inhibitors or
compound 89 somehow cause these conformational changes
to take place, while the I-state would not exist prior to ligand
binding. A conformational selection mechanism for inhibitor
binding requires, instead, that a ligand-free I-state is one of the
TbMetRS conformations in the ensemble of conformations exist-
ing prior to binding the ligand.
Among the eight structures of TbMetRS reported here, there is
no ligand-free structure since we have been unable to obtain
well-diffracting crystals of TbMetRS without methionine.
However, crystal structures of ligand-free MetRS1 subfamily
members have been reported: Thermus thermophilus MetRS
(TtMetRS) (Sugiura et al., 2000) and the tRNA-bound but unoc-
cupied active site structure of Aquifex aeolicus MetRS
(AaMetRS) (Nakanishi et al., 2005). The ligand-free states
(F-states) of these two MetRS1 enzymes have as hallmarks an
unoccupied EMP, an unoccupied AP, an open CP domain and
a flexible KISKS motif (Figures 5C and 5D). In other words, these
ligand-free MetRS1 F-states are similar to the I-states observed
in TbMetRS in complex with inhibitors and with compound 89
(Figures 5B–5D). Given this similarity, it is highly likely that the
F-state of TbMetRS also contains these characteristics, and
hence its F-state is very similar in structure to its I-state. The2012 Elsevier Ltd All rights reserved 1687
Figure 5. TbMetRS I-State Is Similar to F-State
(A) The protein surface of the TbMetRS M-state (pale cyan). In the M-state the
Met binding pocket is narrow and the AP is nonexistent.
(B–D) are identical views as (A). (B) The protein surface of the TbMetRS I-state
(white). Inhibitor 1320 (light pink) is shown in ball and stick model. (C) The
protein surface of the TtMetRS F-state (pale blue). TtMetRS belongs to the
MetRS1 subfamily. (D) The protein surface of the AaMetRS,tRNA F-state
(tRNA-bound but unoccupied active site, pale green). AaMetRS also belongs
to the MetRS1 subfamily. In contrast to the M-state of TbMetRS (A), both the
EMP and the AP are fully formed and accessible in the I-state of TbMetRS (A)
and F-states of MetRS1 (C and D).
See also Figures S9, S10, S11, S12, and S13.
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Inhibitor Binding by T. brucei Met tRNA Synthetasecombination of these data indicate that, even in the crystalline
state, the conformation of subunit B adopts for a small fraction
of the time the F-state in which the methionine is absent, the
EMP and AP are present but unoccupied, the CP moves away,
and the KISKS loop flexes. When these crystals are in a medium
containing inhibitors or compound 89, these small molecules
select the ligand-free F-state for forming the TbMetRS,ligand
complex with the enzyme in an I-state very similar to that to
the F-state (Figure 6). Hence, inhibitor and fragment binding to
the TbMetRS,Met complex occurs largely via the mechanism
of conformational selection, with possibly small structural adap-
tations after initial ligand binding.
It is of interest to contrast the properties of the MetRS1 and
MetRS2 enzymes. In the F-state of MetRS2 enzymes, as seen
in the structures of EcMetRS (Mechulam et al., 1999) and
Pyrococcus abyssi MetRS (PaMetRS)(Crepin et al., 2004), the
EMP is evident but the AP is occluded (Figure S9). Interestingly,
aminoquinolone inhibitors are known to be ineffective against
MetRS2 subfamily (Gentry et al., 2003; Green et al., 2009). This
further supports the conformational selection mechanism for
MetRS1 enzymes, since the conformation compatible with the
inhibitor binding is not available in the F-state of MetRS2. Hence,
there are globally two F-state conformations in MetRS enzymes1688 Structure 20, 1681–1691, October 10, 2012 ª2012 Elsevier Ltddependent on subfamily. The F-state of MetRS1 is comparable
and similar to the I-state of TbMetRS while these states are
different for the MetRS2 enzymes (Figure 5 and Figure S9).
(The basis for the two distinct F-states is further discussed
in the Supplemental Discussion and Figures S10, S11, S12,
and S13.)
Summarizing, the eight structures of TbMetRS, a validated
drug target for African trypanosomiasis, in complex with
a substrate, a product, five inhibitors, and a lowmolecular weight
compound, provide a precise picture of the mode of binding and
the conformational changes occurring in this MetRS1 enzyme
upon binding of a series of potent inhibitors and of a weak
binding compound. These structures provide a precious plat-
form for the further development of desperately needed antitry-
panosomal compounds. Completely unexpectedly, this series of
structures indicates at the same time that conformational
selection is the likely mechanism of the observed ligand binding
by TbMetRS. These results support the idea that conformational
selection plays a major role in ligand binding to proteins
(Bakan and Bahar, 2009; Boehr et al., 2009; Changeux and
Edelstein, 2011).
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Previous attempts to crystallize both the full-length and a catalytically active
N-terminal truncation mutant of TbMetRS (Tb927.10.1500) within the Medical
Structural Genomics of Parasitic Protozoa (MSGPP) consortium (Fan et al.,
2008) were unsuccessful even though the same N-terminal truncation
had been successful in the crystallization of the homologous MetRS from
Leishmania major (LmMetRS) (Larson et al., 2011). In a next approach, this
truncated form (residues 237–773) was chosen for site-directed mutagenesis
of surface residues to promote crystallization through surface entropy reduc-
tion mutagenesis (SER) using suggestions from the SERP server (Goldschmidt
et al., 2007). Instead of mutating residues to alanine as in ‘‘classical’’ SER,
some residues were also mutated to arginine. Several crystal forms were
obtained after exploring multiple SER variants, all remote from the active
site. Crystals used in the current study contain a triple mutation of 452KKE454
to ARA in TbMetRS.
Plasmids carrying this triple mutation were transformed into Escherichia coli
BL21(DE3) for expression. Protein was purified by a Ni-NTA affinity column
followed by overnight cleavage of the N-terminal hexa-histidine tag using 3C
protease at 4C. Cleaved protein was purified by size-exclusion chromatog-
raphy on a Superdex 75 column (Amersham Pharmacia Biotech) using a buffer
containing 25 mM HEPES, 500 mM NaCl, 2 mM DTT, 5% glycerol, 0.025%
NaN3, and 10 mM L-methionine at pH 7.0. Purified protein retained five
residues of the 3C protease cleavage site at the N terminus.
Protein Crystallization
The protein was screened for crystallization leads using a Phoenix crystalliza-
tion robot (Art Robbins Instruments) using a variety of commercially available
sparse matrix screens. One hit from theWizard II screen (Emerald Biosystems)
was optimized to yield diffracting quality crystals. The best crystals were
obtained by vapor diffusion using sitting drops equilibrated at room tempera-
ture against a reservoir containing 2.0–2.3M (NH4)2SO4, 0.2MNaCl, and 0.1M
sodium cacodylate (pH 6.0–6.6). The drops consisted of 1 ml protein at 10 mg/
ml plus 1 ml of the reservoir solution. An additional 1 mM tris(2-carboxyethyl)
phosphine and 10 mM L-methionine were added to the protein solution imme-
diately prior to setting up crystal trays. Crystals grew in 1–2 days at room
temperature.
Compound Synthesis
The synthesis and characterization of the compounds have been described
recently (Shibata et al., 2011). All compounds are based on previously reportedAll rights reserved
Figure 6. A Model for the Binding of Inhibitors through Conformational Selection
The presence of Met (red) stabilizes the M-state as the major population in the crystals. The introduction of ATP andMg2+ (green) by soaking stabilizes a partially
closed active site and shifts the equilibrium toward the P-state. Further, due to the lack of crystal contacts in subunit B to stabilize the CP domain (especially the
CP knuckle) and the KISKSmotif (Figure S2), a minor population of F-state continues to exist in the crystal. The F-state differs from theM-state by the presence of
the EMP and AP. Upon the introduction of inhibitors (blue) or compound 89 (dark blue), the F-state, which is in a conformation compatible with the binding due to
the presence of the EMP and the AP, is stabilized and selected by the inhibitors. Hence themechanism of binding is conformational selection. Abbreviations used
in labels are: MP, methionine pocket; EMP, enlarged methionine pocket; AP, auxiliary pocket; Ad, adenine pocket.
See also Figures S9, S10, S11, S12, and S13.
Structure
Inhibitor Binding by T. brucei Met tRNA Synthetasestructures of bacterial MetRS inhibitors. Compounds 1289, 1312, and 1320
have a substituted benzyl group linked to an aminoquinolone moiety through
an aminopropyl linker (Critchley et al., 2005; Jarvest et al., 2002). The amino-
quinolone moiety is replaced by a benzimidazole moiety in compound 1331Structure 20, 1681–1(Jarvest et al., 2004). Compound 1325 is similar to another reported inhibitor
(Li et al., 2008) where the substituted phenyl group and benzimidazole group
is bridged by a pyrimidine moiety. Compound 89 is a low molecular weight
‘‘fragment,’’ similar to the aminoquinolone moiety of 1289, 1312, and 1320,691, October 10, 2012 ª2012 Elsevier Ltd All rights reserved 1689
Structure
Inhibitor Binding by T. brucei Met tRNA Synthetasefound to increase the melting temperature of TbMetRS in a screen against the
MSGPP fragment cocktail library (Verlinde et al., 2009).
Soaking of Compounds
Attempts to cocrystalize the compounds with TbMetRS failed to yield high-
resolution diffraction data. Following an alternative avenue, TbMetRS,Met
crystals were soaked in a cryosolution containing the compounds. The ratio
of compounds and reservoir and glycerol solutions was carefully adjusted to
minimize precipitation. Typically, crystals were soaked in a 10 ml solution
containing 1 ml of 20 mM inhibitor (or 500 mM 89) in 20% DMSO, 4 ml reservoir
solution, and 5 ml 60% glycerol in protein buffer. Crystals usually disintegrated
upon soaking longer than several minutes and required to be flash frozen in
liquid nitrogen within 1 min.
Data Collection and Structure Determination
Data were collected under cryogenic conditions at three different facilities:
(1) home source facility using 1.54 A˚ wavelength for TbMetRS,Met,
TbMetRS,MAMP, TbMetRS,1289, TbMetRS,1312, TbMetRS,1320, and
TbMetRS,1325; (2) SSRL beamline 11-1 using 0.98 A˚ wavelength for
TbMetRS,1331; and (3) SSRL beamline 9-2 using 0.98 A˚ for TbMetRS,89.
All data were integrated and scaled with the programs Denzo and Scalepack
in HKL2000 (Otwinowski and Minor, 1997). Unmerged output from Scalepack
was also scaled with the program Scala in the CCP4 suite (Collaborative
Computational Project Number 4, 1994) to obtain Rpim (Weiss, 2001) and
CC* (Karplus and Diederichs, 2012) values (Table 1). The initial structure of
TbMetRS,Met was solved by molecular replacement using the coordinates
of LmMetRS (3FKL) (Larson et al., 2011) as the search model with the program
Phaser (McCoy et al., 2007). Iterated building/rebuilding and refinement of
models were performed using Coot (Emsley et al., 2010) and REFMAC5 (Mur-
shudov et al., 1997), respectively. In the final cycles of refinement, protein
structures were refined with translational/libration/screw (TLS) groups identi-
fied by the TLS motion determination server (Painter and Merritt, 2006) before
restrained refinement in REFMAC5. The refined structure of TbMetRS,Met
was then used as search model for molecular replacement of the other struc-
tures. The PRODRG server (Schu¨ttelkopf and van Aalten, 2004) was used to
generate refinement restraints for all ligands. The structure validation server
MolProbity (Chen et al., 2010) was used throughout the process to monitor
the progress of structure determination. All refined structures showed good
statistics with no outliers in Ramachandran plots based on MolProbity. The
final crystallographic refinement statistics are given in the Table 1. Figures
were created and rendered with Pymol (DeLano, 2002).
Aminoacylation Assay
Enzyme activity was quantified by the attachment of [3H]methionine to tRNA
in the presence of the T. brucei MetRS enzyme. Reactions were performed
in 96-well filter plates with Durapore membranes (MSHVN4B10; Millipore) in
volumes of 75 ml. The reaction was performed with 25 mM HEPES (pH 7.9),
10 mM MgCl2, 50 mM KCl, 0.2 mM spermine, 0.1 mg/ml bovine serum
albumin, 2.5 mM dithiothreitol, 1% DMSO, and 1 U/ml pyrophosphatase
(I1643; Sigma). Recombinant enzyme (10 nM) and compound inhibitors (start-
ing concentration varied depending on potency and included 12 serial 2-fold
dilutions) were mixed with the buffer and preincubated for 15 min. To start
the reaction, 400 mg/ml bulk Escherichia coli tRNA (R4251; Sigma), 0.1 mM
ATP, and 250 nM [3H]methionine (80 Ci/mmol) were added. The plate was
incubated without shaking at room temperature for 120 min. The reactions
were stopped by the addition of 100 ml cold 10% trichloroacetic acid. The reac-
tion components were separated from tRNA by filtration through a vacuum
manifold and washed three times with cold 10% trichloroacetic acid. The filter
plates were dried overnight, scintillation fluidwas added, and the counts on the
plates were determined in a scintillation plate counter. Samples were run in
quadruplicate and percent inhibition was calculated using two different
controls (no enzyme and no test compound) with the following formula:
% Inhibition= 1003
ðMnd DtdÞ
ðMndMneÞ;
whereMnd is the average no drug control, Dtd is each test drug value, andMne
is the average no enzyme control. IC50 values were then calculated by
nonlinear regression (sigmoidal dose response) in Prism 3.0.1690 Structure 20, 1681–1691, October 10, 2012 ª2012 Elsevier LtdThermal Shift Assay
The thermal shift assay was performed as previously described (Shibata et al.,
2011) with 0.42 mg/ml of TbMetRS, 100 mM of 1289, 1312, 1325, or 1331, or
50 mM of 1320, 10 mM ATP magnesium salt, 10 mM L-methionine, and 5%
dimethyl sulfoxide. The inclusion of 10 mM ATP and methionine in the assay
buffer was to suppress the overall thermal shift signal so that only tight-binding
inhibitors could cause a significant shift in the melting temperature (Tm) of
MetRS. The assay for compound 89 was performed at 800 mM of 89 in the
absence of Met, ATP, and Mg2+. The assays were performed twice indepen-
dently in triplicate in each experiment.
ACCESSION NUMBERS
Coordinates and structure factors for TbMetRS,Met, TbMetRS,MAMP,
TbMetRS,1289, TbMetRS,1312, TbMetRS,1320, TbMetRS,1325,
TbMetRS,1331 and TbMetRS,89 were deposited in the Protein Data Bank
under accession codes 4EG1, 4EG3, 4EG4, 4EG5, 4EGA, 4EG6, 4EG7, and
4EG8, respectively.
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